New analysis confirms canagliflozin’s cardiovascular and kidney benefits in older adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age.

New Study Says LSD and Psilocybin Could Outperform Opioids for Pain, Without Developing Tolerance

Most people put pain and depression in two separate categories, myself included. But when a doctor recently explained that PTSD and depression hurt too, the

November 29, 2023

Questions about childhood weight can help identify increased mortality risk in adults with obesity

Being asked whether you considered yourself a normal weight, plumper or thinner as a child when attending a doctor’s appointment as an adult might appear

May 13, 2024

Hepatitis C patients may benefit from revaccination against hepatitis B after treatment

Recently published research from the University of Minnesota Medical School suggests individuals with hepatitis C should consider revaccination for hepatitis B. The study was published

September 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.